AstraZeneca Reports P-III Trial (DUO-O) of Lynparza (olaparib) and Imfinzi (durvalumab) for Advanced Ovarian Cancer without Tumour BRCA Mutations
Shots:
- The company highlighted the results from a planned interim analysis of the P-III trial evaluating Imfinzi + Pt-based CT & bevacizumab vs CT + bevacizumab in a ratio (1:1:1) in ~1200 patients at 179 study locations, followed by maintenance treatment with Imfinzi & bevacizumab with/out Lynparza
- Lynparza, Imfinzi, CT & bevacizumab achieved an improvement in PFS. Imfinzi, CT + bevacizumab showed a numerical improvement in PFS but did not reach statistical significance at this interim analysis while OS & other 2EPs are immature and will be formally assessed at a subsequent analysis
- The safety & tolerability were consistent with prior trials & known profiles of the individual therapies. The results will be shared with health authorities
Ref: lynparza and imfinzi | Image: lynparza and imfinzi
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
